Chapter 3
Potential for Increased Investment Activity in 2025
U.S. Life Sciences Outlook 2025
2 Minute Read
2 Minute Read
Sales transactions of life sciences lab/R&D properties hit their lowest level in over a decade in 2024, largely due to high interest rates and weak supply-and-demand fundamentals.
CBRE Research projects marginally higher investment sales in 2025 for all commercial real estate sectors based on improved macroeconomic trends, lower interest rates and greater demand. Life sciences investment activity may see a slight uptick, although the sector’s surge in new supply in H1 2025 will be a headwind.
Figure 28: Annual Investment Volume of R&D Properties
While conventional office properties have seen cap rates jump to levels not seen in over a decade, cap rates for life sciences properties appeared to stabilize in 2024 and remained below levels a decade ago.
CBRE expects the 10-year Treasury yield to remain above 4% in 2025, suggesting that any potential decline in life sciences cap rates will be marginal.
Figure 29: Average Cap Rates for Office and R&D Properties
Related Insights
-
Article | Intelligent Investment
Business Insights | The Flip Side: Five Things Every Property Manager Should Understand About Creating Value
November 20, 2026
Drawing on 20 years in institutional asset management, Gareth Cochrane shares five things property managers should understand to protect income, reduce risk and create long-term value throughout an asset’s lifecycle.